# A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of TBI-223 in Healthy Adults

> **NCT03758612** · PHASE1 · COMPLETED · sponsor: **Global Alliance for TB Drug Development** · enrollment: 86 (actual)

## Conditions studied

- Tuberculosis
- Tuberculosis, Pulmonary

## Interventions

- **DRUG:** TBI-223 oral suspension
- **DRUG:** TBI-223 enteric capsule
- **DRUG:** TBI-223 SR Tablet Prototype 1
- **DRUG:** TBI-223 SR Tablet Prototype 2
- **DRUG:** TBI-223 SR Tablet Prototype 3
- **DRUG:** TBI-223 IR Tablet
- **DRUG:** Placebo suspension

## Key facts

- **NCT ID:** NCT03758612
- **Lead sponsor:** Global Alliance for TB Drug Development
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-16
- **Primary completion:** 2020-03-15
- **Final completion:** 2020-03-15
- **Target enrollment:** 86 (ACTUAL)
- **Last updated:** 2024-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03758612

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03758612, "A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of TBI-223 in Healthy Adults". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03758612. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*